Structure Therapeutics (GPCR) Operating Leases (2023 - 2026)

Structure Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Operating Leases fell 37.78% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (down 37.78% YoY), while the FY2025 annual figure was $3.6 million, up 66.77% from the prior year.
• Operating Leases for Q1 2026 stood at $3.2 million, down from $3.6 million in the prior quarter.
• The five-year high for Operating Leases was $5.1 million in Q1 2025, with the low at $2.2 million in Q4 2024.
• The 4-year median for Operating Leases is $3.5 million (2024), against an average of $3.6 million.
• The sharpest annual moves came in 2024 and 2025: Operating Leases slumped 46.08% in 2024, then surged 66.77% in 2025.
• Structure Therapeutics' Operating Leases stood at $4.0 million in 2023, then plunged by 46.08% to $2.2 million in 2024, then soared by 66.77% to $3.6 million in 2025, then declined by 11.8% to $3.2 million in 2026.
• Business Quant data shows GPCR's Operating Leases at $3.2 million in Q1 2026, $3.6 million in Q4 2025, and $4.3 million in Q3 2025.